Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 9Pathologic Complete Response 1Lymphatic Metastasis 1Carcinoma, Squamous Cell 1

Interventions

Oxaliplatin 3Fluorouracil 3Radiotherapy 2Immune Checkpoint Inhibitors 2Endoscopy 2Drug Therapy 2Chemoradiotherapy 2toripalimab 1tislelizumab 1pembrolizumab 1X-Rays 1Tretinoin 1TP protocol 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proctectomy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Leucovorin 1Immunotherapy 1Immunohistochemistry 1Esophagectomy 1Epirubicin 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Docetaxel 1Diffusion Magnetic Resonance Imaging 1Cisplatin 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × TP protocol × Gastrointestinal × Clear all
NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Sun Yat-sen University

Phase 2 Unknown
44 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡